2020
DOI: 10.1007/s00432-020-03340-5
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

5
19
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(24 citation statements)
references
References 24 publications
5
19
0
Order By: Relevance
“…old, which was consistent with the results of previous studies [ 32 , 33 ]. We also confirmed that TP53 mutation did not affect the prognosis of patients with LUAD, it was consistent with the result of the study by Szymanowska, A., et al [ 34 – 39 ].…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…old, which was consistent with the results of previous studies [ 32 , 33 ]. We also confirmed that TP53 mutation did not affect the prognosis of patients with LUAD, it was consistent with the result of the study by Szymanowska, A., et al [ 34 – 39 ].…”
Section: Discussionsupporting
confidence: 93%
“…We also confirmed that TP53 mutation did not affect the prognosis of patients with LUAD, it was consistent with the result of the study by Szymanowska, A., et al [ 34 – 39 ]. However, other studies suggested that patients with mutation of the TP53 gene had a poor prognosis [ 15 , 32 , 33 , 40 , 41 ]. This phenomenon was worth studying.…”
Section: Discussionmentioning
confidence: 99%
“…We also studied the associations of mutations with clinical features and outcomes. We found that the TP53 gene had a higher mutation rate in people younger than or equal to 65 years old, reaching 53.8%, and it was only 40% in people over 65 years old, which was consistent with the results of previous studies [32,33]. We also con rmed that TP53 mutations did not affect the prognosis of patients with LUAD, it was consistent with the result of the study by Szymanowska, A., et al [34][35][36][37][38][39].…”
Section: Discussionsupporting
confidence: 92%
“…We also con rmed that TP53 mutations did not affect the prognosis of patients with LUAD, it was consistent with the result of the study by Szymanowska, A., et al [34][35][36][37][38][39]. However, other studied suggested that patients with mutations of the TP53 gene had a poor prognosis [15,32,33,40,41]. This phenomenon was worth studying.…”
Section: Discussionsupporting
confidence: 91%
“…Catherine Labbé et al demonstrated that patients with dual TP53/EGFR mutations, especially missense mutations, had marginally lower response rates and shorter PFS when treated with EGFR TKI therapy [23]. Feng Wang et al also showed that mutant TP53 is a poor prognostic factor in LUAD patients, and the prognosis of TP53/EGFR co-mutation is worse [24]. They also demonstrated that, there was no signi cant difference in OS bene t when patients with EGFR mutations were compared with those with EGFR wild type.…”
Section: Discussionmentioning
confidence: 99%